• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.

作者信息

Bianchine J R, Messiha F S, Hsu T H

出版信息

Clin Pharmacol Ther. 1972 Jul-Aug;13(4):584-94. doi: 10.1002/cpt1972134584.

DOI:10.1002/cpt1972134584
PMID:5042372
Abstract
摘要

相似文献

1
Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.帕金森病中的外周芳香族L-氨基酸脱羧酶抑制剂。II. 对L-2-¹⁴C-多巴代谢的影响
Clin Pharmacol Ther. 1972 Jul-Aug;13(4):584-94. doi: 10.1002/cpt1972134584.
2
Effects of peripheral aromatic L-amino acids decarboxylase inhibitor on L-(2- 14 C)-3,4-dihydroxyphenylalanine metabolism in man.
Biochem Pharmacol. 1972 Aug 1;21(15):2144-7. doi: 10.1016/0006-2952(72)90169-4.
3
[Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].[在患有抑郁和帕金森综合征的患者中，与左旋多巴和地昔帕明相关的脱羧酶抑制剂作用下儿茶酚胺代谢的改变]
Encephale. 1971 May-Jun;60(3):189-209.
4
[Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].
Clin Chim Acta. 1971 Jun;33(1):111-5. doi: 10.1016/0009-8981(71)90257-9.
5
[Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Rev Med Chil. 1973 Jun;101(6):452-5.
6
Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.左旋多巴治疗帕金森病：外周抑制剂增强中枢效应
N Engl J Med. 1972 Jan 6;286(1):8-14. doi: 10.1056/NEJM197201062860102.
7
Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.采用气相色谱法对人体中L-3,4-二羟基苯丙氨酸（L-DOPA）的代谢和排泄进行的研究。
Chem Pharm Bull (Tokyo). 1972 Apr;20(4):759-64. doi: 10.1248/cpb.20.759.
8
Effect of L-aromatic amino acid decarboxylase inhibition on metabolism of dihydroxyphenylalanine by isolated perfused rat liver.
Biochem Pharmacol. 1972 Nov 15;21(22):2977-89. doi: 10.1016/0006-2952(72)90191-8.
9
Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.给抑郁症患者同时服用外周脱羧酶抑制剂和左旋多巴。
Lancet. 1970 May 2;1(7653):908-11. doi: 10.1016/s0140-6736(70)91044-5.
10
The effect of methyldopa on the excretion of catecholamines in patients with extrapyramidal disorders.
Confin Neurol. 1967;29(2):78-80. doi: 10.1159/000103681.

引用本文的文献

1
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.采用 LC-HRMS 对健康人体参与者血浆中的 foslevodopa/foscarbidopa 进行代谢物分析，结果表明与给予左旋多巴/卡比多巴肠凝胶相比无明显差异。
Pharmacol Res Perspect. 2024 Apr;12(2):e1190. doi: 10.1002/prp2.1190.
2
A novel pathway of levodopa metabolism by commensal Bifidobacteria.共生双歧杆菌左旋多巴代谢的新途径。
Sci Rep. 2023 Nov 6;13(1):19155. doi: 10.1038/s41598-023-45953-z.
3
Relationship Between Gut Bacteria and Levodopa Metabolism.
肠道细菌与左旋多巴代谢的关系。
Curr Neuropharmacol. 2023;21(7):1536-1547. doi: 10.2174/1570159X21666221019115716.
4
Gut bacterial deamination of residual levodopa medication for Parkinson's disease.肠道细菌对帕金森病残留左旋多巴药物的脱氨作用。
BMC Biol. 2020 Oct 20;18(1):137. doi: 10.1186/s12915-020-00876-3.
5
Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease.肠道细菌和饮食对帕金森病治疗中药物药代动力学的影响
Front Neurol. 2019 Oct 15;10:1087. doi: 10.3389/fneur.2019.01087. eCollection 2019.
6
Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.蛋白质限制饮食改善帕金森病运动波动
Front Aging Neurosci. 2017 Jun 28;9:206. doi: 10.3389/fnagi.2017.00206. eCollection 2017.
7
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?药物诱发的帕金森病运动障碍。临床管理的成功是否应取决于运动障碍幅度的改善，而不是运动障碍的改善？
BMC Med. 2013 Mar 20;11:76. doi: 10.1186/1741-7015-11-76.
8
Plasma dopa concentrations after different preparations of levodopa in normal subjects.正常受试者中不同左旋多巴制剂给药后的血浆多巴浓度。
Br J Clin Pharmacol. 1976 Dec;3(6):983-90. doi: 10.1111/j.1365-2125.1976.tb00347.x.
9
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.帕金森病中的刺蒺藜豆：一项双盲临床与药理学研究。
J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7. doi: 10.1136/jnnp.2003.028761.
10
Clinical pharmacokinetics of anti-parkinsonian drugs.抗帕金森病药物的临床药代动力学
Clin Pharmacokinet. 1987 Sep;13(3):141-78. doi: 10.2165/00003088-198713030-00002.